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Streptococcus pneumoniae infections can be prevent-
ed by using new conjugate vaccines, but these vaccines
have limited serogroup coverage. We report the first
serogrouping data from carried and invasive isolates
obtained from children and adults in Malawi. The 7-valent
vaccine would cover 41% of invasive isolates from children
and 25% from adults. A 9-valent vaccine, including types 1
and 5, would cover 66% of invasive isolates from children
and 55% from adults. 
S
treptococcus pneumoniae is the leading cause of bacte-
rial meningitis in both children and adults in Malawi, as
well as an important cause of pneumonia, bacteremia, and
death for all ages (1,2). The incidence of S. pneumoniae
was reduced in the United States and Europe after the
licensing of a 7-valent pneumococcal conjugate vaccine
(3), and the Global Alliance for Vaccines and
Immunization (available from: URL: http://www.vac-
cinealliance.org) has plans to expand the use of the vaccine
to sub-Saharan Africa (4). However, few data from the
central African region exist on which to base a pneumo-
coccal conjugate vaccination program. 
Methods
Collection of Pneumococcal Isolates
Queen Elizabeth Central Hospital, the main referral
hospital for southern Malawi, admits approximately
12,000 children and 10,000 adults per year. From 1996 to
1998, blood cultures and cerebrospinal fluid (CSF) sam-
ples were taken from patients admitted to emergency in
whom they were indicated. Guidelines suggest that blood
cultures should be taken from all febrile patients and lum-
bar puncture performed if two of three clinical findings
(headache, fever, and altered consciousness) indicate
meningitis. S. pneumoniae were identified from these sam-
ples by using colony morphology on blood agar, optochin
sensitivity, and Gram stain. All S. pneumoniae isolates col-
lected from these samples were stored in bead and broth
bacterial cryopreservers (Prolab Diagnostics, Ontario,
Canada) at –80°C for serogrouping at a later date. 
Carriage Study
From March to July 1998, we collected samples from
250 children and 500 adults by using a single posterior
nasal swab, with a sterile cotton swab dipped in saline. The
swab was then directly rolled on to a sheep blood agar
plate and incubated overnight. Colony subcultures with
typical morphologic findings were placed on a second
blood agar plate with an optochin disc and cultured at 35°C
and 5% CO2. After 18–24 hours, colonies selected on the
basis of typical colony morphologic findings and Optochin
sensitivity were stored at –80°C.
Serogrouping
Stored isolates were recultured for typing by using both
sheep blood agar plates and enrichment broth (brain heart
infusion and Vitox [Oxoid, Basingstoke, U.K.]).
Pneumococcal serogrouping was performed with the
Quellung reaction with a standard technique (5) and a
diagnostic kit from Statens Serum Institut (SSI),
Copenhagen, Denmark. This diagnostic kit uses a matrix to
group pneumococci covered by the 23-valent pneumococ-
cal vaccine but does not allow typing of pneumococci to
the 90 described capsular types. All serogrouping was per-
formed by two investigators (S.B.G. was trained at the
World Health Organization [WHO] Pneumococcal
Reference Laboratory at SSI, Copenhagen; he trained S.K.
who sent a set of serogrouped isolates and isolates that
could not be typed by kit to SSI for confirmation of accu-
rate technique). 
Results
Atotal of 628 invasive pneumococcal isolates were col-
lected from the emergency pediatric and medical service.
These isolates consisted of 114 pediatric blood cultures,
206 pediatric CSF samples, 208 adult blood cultures, and
100 adult CSF samples. In the carriage study, 105 isolates
were collected from 250 children (42% carriage) and 54
isolates were collected from 500 adults (10.8% carriage).
Because of a storage accident, some isolates (predominant-
ly pediatric CSF samples) thawed and were not recovered.
The total isolates available for serogrouping was 428
(Figure). 
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Types 1 and 5 accounted for 27% and 23% of the isolates
from pediatric blood and CSF samples, respectively, and
29% and 31% of the isolates from adult blood and CSF
samples, respectively. The potential coverage of the 7-
valent conjugate vaccine, which excludes these types, was
poor. A high percentage of non–23-valent vaccine type
pneumococci existed in adult invasive isolates (35%). A
sample of 10 such isolates was sent to the WHO
Pneumococcal Reference Laboratory for confirmation of
serogrouping. Five strains could not be typed or were
acapsulate (“rough”) pneumococci, three were not vaccine
strains (28F, 16F, and 31), one was S. oralis, and one was
a misclassified type 7C.
Discussion
These data are the only recent pneumococcal
serogrouping data from children and adults available in
this region of Africa. As expected, the data showed high
rates of pneumococcal carriage in children and lower rates
in adults. The pattern of serogroups showed higher rates of
types 1 and 5 than that reported from the United States and
Europe. The pattern seen in Malawi is similar to that from
West Africa (6). A higher incidence of non–23-valent vac-
cine type pneumococci occurred in our study compared
with the incidence in other studies, particularly in our adult
isolates; this finding may reflect the high incidence of HIV
seropositivity in our population. Recent data from South
Africa indicate an increase of typical pediatric carried
types (non–23-valent types), causing disease in HIV-
infected adults (7). Other recent data are available from
coastal Kenya (8), but both of these datasets represent a
different population, in terms of ethnic diversity, geo-
graphic separation, and HIV seroprevalence. 
The potential coverage of invasive pneumococcal iso-
lates offered by the available 7-valent vaccine was poor in
Malawi. Previous estimates have suggested that conjugate
vaccine coverage in this region would be 70% to 88% (9).
We tested a large number of isolates; although some were
lost before serogrouping could be performed, the lost iso-
lates probably did not alter the serogroup distribution in
our study. In 1980 before the 23-valent polysaccharide
vaccine was formulated, serogroups 1 and 5 were consid-
ered essential in vaccines for use in Africa (6); a 9-valent
vaccine, including serogroups 1 and 5, is already under
trial in the Gambia and South Africa (4). Our study indi-
cates that the inclusion of types 1 and 5 will make a sub-
stantial difference to the efficacy of the vaccine in Malawi.
Alternatively, protein vaccines may have high efficacy
against a still wider range of pneumococci.
Antibiotic use is very low in Malawi compared with
other parts of the world, and Pneumocystis carinii pneu-
monia prophylaxis is almost unknown because of the lack
of healthcare provision. Very low rates of pneumococcal
resistance to penicillin (14%), chloramphenicol (24%),
and erythromycin (1%) exist in Malawi (10). However,
resistance to co-trimoxazole is high (94%) because of the
use of sulphamethoxazole-pryrimethamine as firstline
anti-malarial drug therapies (11). We were not able to com-
pare the incidence of different serotypes between resistant
and nonresistant strains because of the small numbers of
penicillin-, chloramphenicol-, or erythromycin-resistant
isolates and the small number of cotrimoxazole-sensitive
isolates.
HIVinfection is a particular problem in Malawi, both in
adults and children. An estimated 18% of pediatric hospi-
tal patients, 72% of adult hospital patients, and 95% of
adults with invasive pneumococcal disease are seroposi-
tive for HIV in Blantyre, Malawi (12). Conjugate vaccine
is safe and immunogenic in HIV-infected persons (13), and
conjugate vaccine was shown to be effective in HIV-infect-
ed children, albeit at lower levels than in non–HIV-infect-
ed children (14). The vaccine coverage of pneumococcal
types, vaccine percentage efficacy, and stage of HIV dis-
ease in vaccine recipients are critical determinants of
whether this strategy will be of value in adults. However,
exposure to children carrying pneumococci is a known risk
factor for invasive pneumococcal disease in adults (4).
Therefore, reduced carriage of disease-causing pneumo-
coccal strains in children could reduce the adult incidence
of invasive pneumococcal disease in this population.
Pneumococcal serogroups will continue to be monitored in
disease-causing isolates so that vaccine can be implement-
ed in a timely manner.
Acknowledgments
We thank the volunteers, staff, and patients of the Queen
Elizabeth Central Hospital, Blantyre, Malawi, for their coopera-
tion with this study; Helle Bossen Konradsen and the staff of the
World Health Organization Pneumococcal Reference Laboratory,
748 Emerging Infectious Diseases • Vol. 9, No. 6, June 2003
DISPATCHES
Figure. The cumulative percentage of all pneumococcal isolates
plotted by source (see key). Serogroups covered by the 7-valent
vaccine are plotted to the left of the heavy vertical line, and the
potential 9-valent coverage is illustrated by the dotted vertical line.Statens Serum Institut, Copenhagen, Denmark, for training in
serogrouping and confirmation of results; and the laboratory staff
of the Wellcome Trust Research Laboratories, Blantyre, Malawi,
for technical assistance.
This work forms part of the Malawi-Liverpool-Wellcome
Trust Programme of Research in Clinical Tropical Medicine.
Financial support was provided by from the Wellcome Trust of
Great Britain.
Dr. Gordon holds a Wellcome Trust Career Development
Fellowship. His main research interest is susceptibility to infec-
tion in HIV-infected adults and the role of pulmonary defense
mechanisms. 
References
1. Molyneux EM, Walsh AL, Forsyth H, Tembo M, Mwenechanya J,
Kayira K, et al. Dexamethasone treatment in childhood bacterial
meningitis in Malawi: a randomised controlled trial. Lancet
2002;360:211–8.
2. Gordon SB, Walsh AL, Chaponda M, Gordon MA, Soko D,
Mbwvinji M, et al. Bacterial meningitis in Malawian adults: pneumo-
coccal disease is common, severe, and seasonal. Clin Infect Dis
2000;31:53–7.
3. Black S, Shinefield H, Fireman B. Efficacy, safety, and immuno-
genicity of heptavalent pneumococcal conjugate vaccine in children.
Northern California Kaiser Permanente Vaccine Study Center Group.
Pediatr Infect Dis J 2000;19:187–95.
4. Whitney CG. The potential of pneumococcal conjugate vaccines for
children. Pediatr Infect Dis J 2002;21:961–70.
5. Sorensen UBS. Typing of pneumococci by using 12 pooled antisera.
J Clin Microbiol 1993;31:2097–100.
6. Greenwood BM, Hassan-King M, Onyemelukwe G, Macfarlane JT,
Tubbs HR, Tugwell PJ, et al. Pneumococcal serotypes in West Africa.
Lancet 1980;1:360.
7. Crewe-Brown HH, Karstaedt AS, Saunders GL, Khoosal M, Jones N,
Wasas A, et al. Streptococcus pneumoniae blood culture isolates from
patients with and without human immunodeficiency virus infection:
alterations in penicillin susceptibilities and in serogroups or
serotypes. Clin Infect Dis 1997;25:1165–72.
8. Scott JA, Hall AJ, Hannington A, Edwards R, Mwarumba S, Lowe B,
et al. Serotype distribution and prevalence of resistance to ben-
zylpenicillin in three representative populations of Streptococcus
pneumoniae isolates from the coast of Kenya. Clin Infect Dis
1998;27:1442–50.
9. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococ-
cal serogroups cause the most invasive disease: implications for con-
jugate vaccine formulation and use, part I. Clin Infect Dis
2000;30:100–21.
10. Gordon MA, Walsh AL, Chaponda M, Soko D, Mbvwinji M,
Molyneux ME, et al. Bacteraemia and mortality among adult medical
admissions in Malawi—predominance of non-typhi salmonellae and
Streptococcus pneumoniae. J Infect 2001;42:44–9.
11. Feikin DR, Dowell SF, Nwanyanwu OC, Klugman KP, Kazembe PN,
Barat LM, et al. Increased carriage of trimethoprim/sulfamethoxa-
zole-resistant Streptococcus pneumoniae in Malawian children after
treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis
2000;181:1501–5.
12. Gordon SB, Chaponda M, Walsh AL, Whitty CJ, Gordon MA,
Machili CE, et al. Pneumococcal disease in HIV-infected Malawian
adults: acute mortality and long-term survival. AIDS
2002;16:1409–17.
13. Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-
Steiner S, et al. Randomized trial of the quantitative and functional
antibody responses to a 7-valent pneumococcal conjugate vaccine
and/or 23-valent polysaccharide vaccine among HIV-infected adults.
Vaccine 2001;20:545–53.
14. Madhi SA. Vaccinating against Streptococcus pneumoniae–the new
generation vaccine. South African Respiratory Journal 2002;8:35–42.
Address for correspondence: Stephen Gordon, Wellcome Trust Research
Laboratories, P.O. Box 30096, Blantyre, Malawi; fax: +265 1 675744;
email: sgordon@mlw.medcol.mw
Emerging Infectious Diseases • Vol. 9, No. 6, June 2003 749
DISPATCHES
The print journal is available at no charge to public health professionals
YES, I would like to receive Emerging Infectious Diseases.
Please print your name and business
address in the box and return by fax to
404-371-5449 or mail to
EID Editor
CDC/NCID/MS D61
1600 Clifton Road, NE
Atlanta, GA 30333
Moving? Please give us your new address (in the box) and print the number of your old
mailing label here_________________________________________
	



